Retatrutide (also known as "Reta" or "Rata") is one of the most talked-about peptides in research on metabolism, appetite, and weight. Many compare it to the well-known "weight-loss injections" — Ozempic, Wegovy andMounjaro — so on this page we'll also explain what's similar and what's different between them, alongside factual, research-based information: what it is, how it works, what the clinical trials showed, and its regulatory status.
The information in this article is for educational purposes only and does not constitute medical advice or recommendation. All products on the site are intended for research only and are not intended for human or veterinary use.
What is Retatrutide?
Retatrutide is a synthetic peptide classified as atriple agonist — a molecule designed to activate three hormone receptors simultaneously: GLP-1, GIP andGlucagon. These three pathways are involved in regulating appetite, insulin secretion, and energy metabolism. The compound was developed by Eli Lilly (studied under the name LY3437943) and is in advanced stages of clinical research.
How does Retatrutide work? The mechanism in brief
The idea behind a "triple agonist" is to combine three complementary actions:
- GLP-1 — a pathway involved in satiety and in regulating blood sugar levels.
- GIP — an additional gut hormone that influences metabolism and the insulin response.
- Glucagon — involved in energy expenditure and in liver metabolism.
This combination is what sets Retatrutide apart from compounds that act on only one or two pathways.
What does the clinical research show?
Notable results were published in 2023 in the medical journal New England Journal of Medicine. In a Phase 2 trial, participants who received the high dose showed an average reduction of about24% in body weight over 48 weeks. It's important to emphasize: this is a result achieved ina controlled clinical-trial setting under medical supervision, with a compound that is investigational and not approved for therapeutic use. As with other compounds in the family, side effects were also examined — mainly in the digestive system.
Retatrutide vs. Ozempic, Wegovy, and Mounjaro
The three most-discussed compounds in the "weight-loss injections" space differ in the number of receptors they activate. Here is the difference, including the well-known brand names:
- Semaglutide — a single agonist (GLP-1). Known by the brand names Ozempic andWegovy.
- Tirzepatide — a dual agonist (GLP-1 + GIP). Known by the brand name Mounjaro (and in the US, also Zepbound).
- Retatrutide — a triple agonist (GLP-1 + GIP + Glucagon), and still in the research stage (it does not yet have a brand name).
Regulatory status and research use
As of today, Retatrutide is a compound that is investigational in research stages, andis not approved by the FDA, the EMA, or the Ministry of Health for therapeutic use. Compounds sold for research purposes are not a substitute for medical advice or treatment, and must not be used in humans. Anyone interested in weight management should consult a qualified physician.
Frequently asked questions
"Reta" and "Rata" — what do they refer to?
These are common Hebrew nicknames for Retatrutide.
Is Retatrutide FDA-approved?
No; as of today it is in clinical research stages, and its use is for research purposes only.
What is the difference between Retatrutide and Ozempic or Mounjaro?
Mainly in the number of receptors and the mechanism: Ozempic and Wegovy (Semaglutide) act on one receptor, Mounjaro (Tirzepatide) on two, and Retatrutide was designed to act on three receptors.
For information on the research products: Retatrutide 20mg · Retatrutide 40mg. To calculate dilution, you can use theour dilution calculator, and for questions about storage and reconstitution, see the the FAQ page.
The information in this article is general and for educational purposes only and does not constitute medical advice. The products on the site are intended for research only and are not intended for human or veterinary use.
